{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:41:40Z","timestamp":1791312100166,"version":"4.3.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071887, 81671656"],"award-info":[{"award-number":["82071887, 81671656"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11934-023-01187-0","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T03:01:41Z","timestamp":1699412501000},"page":"561-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management Strategy for Prostate Imaging Reporting and Data System Category 3 Lesions"],"prefix":"10.1007","volume":"24","author":[{"given":"Zhen","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaogang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiubai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"issue":"3","key":"1187_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5152\/tud.2018.12144","volume":"44","author":"CP Smith","year":"2018","unstructured":"Smith CP, T\u00fcrkbey B. PI-RADS v2: Current standing and future outlook. Turk J Urol. 2018;44(3):189\u201394. https:\/\/doi.org\/10.5152\/tud.2018.12144.","journal-title":"Turk J Urol"},{"issue":"1118","key":"1187_CR2","doi-asserted-by":"publisher","first-page":"20191050","DOI":"10.1259\/bjr.20191050\u25cf\u25cf","volume":"94","author":"A Wadera","year":"2021","unstructured":"\u2022\u2022\u00a0Wadera A, et al. Impact of PI-RADS Category 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: a systematic review and meta-analysis. Br J Radiol. 2021;94(1118):20191050.\u00a0https:\/\/doi.org\/10.1259\/bjr.20191050.\u00a0The study found that PI-RADS category 3 lesions can significantly impact the diagnostic test accuracy of MRI for prostate cancer detection. This is the foundation for paying attention to PI-RADS 3 lesions.","journal-title":"Br J Radiol"},{"issue":"3","key":"1187_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/2090598x.2022.2067615","volume":"20","author":"A Nowier","year":"2022","unstructured":"Nowier A, et al. Performance of multi-parametric magnetic resonance imaging through PIRADS scoring system in biopsy na\u00efve patients with suspicious prostate cancer. Arab J Urol. 2022;20(3):121\u20135. https:\/\/doi.org\/10.1080\/2090598x.2022.2067615.","journal-title":"Arab J Urol"},{"key":"1187_CR4","doi-asserted-by":"publisher","unstructured":"Schoots IG.\u00a0MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?. Transl Androl Urol. 2018;7(1):70\u201382.\u00a0https:\/\/doi.org\/10.21037\/tau.2017.12.31.","DOI":"10.21037\/tau.2017.12.31"},{"key":"1187_CR5","doi-asserted-by":"publisher","unstructured":"Lim CS, et al.\u00a0Utility of machine learning of apparent diffusion coefficient (ADC) and T2-weighted (T2W) radiomic features in PI-RADS version 2.1 category 3 lesions to predict prostate cancer diagnosis. Abdom Radiol (NY). 2021;46(12):5647\u20135658. https:\/\/doi.org\/10.1007\/s00261-021-03235-0.","DOI":"10.1007\/s00261-021-03235-0"},{"key":"1187_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejrad.2019.02.031\u25cf\u25cf","volume":"114","author":"I Hermie","year":"2019","unstructured":"\u2022\u2022 Hermie I, et al. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center. Eur J Radiol. 2019;114:92\u20138. https:\/\/doi.org\/10.1016\/j.ejrad.2019.02.031. The study found that prostate volume and the ratio of ADC tumor on ADC of the contralateral prostate have the potential to predict csPCa in PI-RADS 3 lesions with a sensitivity of 59% and specificity of 88%. This study explores useful clinical imaging indicators for diagnosing csPCa in PI-RADS 3 lesions.","journal-title":"Eur J Radiol"},{"issue":"4","key":"1187_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5489\/cuaj.6781","volume":"15","author":"CS Lim","year":"2021","unstructured":"Lim CS, et al. When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy. Can Urol Assoc J. 2021;15(4):115\u201321. https:\/\/doi.org\/10.5489\/cuaj.6781.","journal-title":"Can Urol Assoc J"},{"key":"1187_CR8","doi-asserted-by":"publisher","unstructured":"Yang S, et al.\u00a0Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy. Transl Androl Urol. 2020;9(3):1252\u20131261.\u00a0https:\/\/doi.org\/10.21037\/tau-19-755.","DOI":"10.21037\/tau-19-755"},{"issue":"5","key":"1187_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/bju.15563\u25cf\u25cf","volume":"129","author":"RG Rahota","year":"2022","unstructured":"\u2022\u2022 Rahota RG, et al. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens. BJU Int. 2022;129(5):621\u20136. https:\/\/doi.org\/10.1111\/bju.15563. The study found that PI-RADS 3 lesions exhibited aggressive features in almost 40% of cases, and PSA density and presence of csPCa on targeted biopsy are independent predictive factors for high grade and\/or extraprostatic disease. This study elucidates the pathological features of PI-RADS 3 lesions and provides the proportion of those with malignant characteristics.","journal-title":"BJU Int"},{"issue":"3","key":"1187_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5152\/tud.2017.01058","volume":"43","author":"M Scialpi","year":"2017","unstructured":"Scialpi M, et al. Score 3 prostate lesions: a gray zone for PI-RADS v2. Turk J Urol. 2017;43(3):237\u201340. https:\/\/doi.org\/10.5152\/tud.2017.01058.","journal-title":"Turk J Urol"},{"issue":"4","key":"1187_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5489\/cuaj.7262","volume":"15","author":"C Morash","year":"2021","unstructured":"Morash C. What do you do with PI-RADS-3? Can Urol Assoc J. 2021;15(4):122. https:\/\/doi.org\/10.5489\/cuaj.7262.","journal-title":"Can Urol Assoc J"},{"key":"1187_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.urology.2022.01.020","volume":"164","author":"D Versalle","year":"2022","unstructured":"Versalle D, et al. Practice-level variation in the decision to biopsy prostate imaging-reporting and data system 3 lesions in favorable-risk prostate cancer patients. Urology. 2022;164:191\u20136. https:\/\/doi.org\/10.1016\/j.urology.2022.01.020.","journal-title":"Urology"},{"key":"1187_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.euros.2021.03.004","volume":"27","author":"HC Kang","year":"2021","unstructured":"Kang HC, et al. Accuracy of prostate magnetic resonance imaging: reader experience matters. Eur Urol Open Sci. 2021;27:53\u201360. https:\/\/doi.org\/10.1016\/j.euros.2021.03.004.","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"1187_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4081\/aiua.2021.2.139","volume":"93","author":"P Pepe","year":"2021","unstructured":"Pepe P, et al. mpMRI PI-RADS score 3 lesions diagnosed by reference vs affiliated radiological centers: our experience in 950 cases. Arch Ital Urol Androl. 2021;93(2):139\u201342. https:\/\/doi.org\/10.4081\/aiua.2021.2.139.","journal-title":"Arch Ital Urol Androl"},{"key":"1187_CR15","unstructured":"Salah F.\u00a0Guidelines needed to standardize care for PI-RADS 3 Patients. RSNA 2020 session, 2020.\u00a0SSGU07.\u00a0https:\/\/dailybulletin.rsna.org\/dailybulletin\/index.cfm?pg=20mon07"},{"issue":"1","key":"1187_CR16","doi-asserted-by":"publisher","first-page":"6746","DOI":"10.1038\/s41598-022-10859-9","volume":"12","author":"M Boschheidgen","year":"2022","unstructured":"Boschheidgen M, et al. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate. Sci Rep. 2022;12(1):6746. https:\/\/doi.org\/10.1038\/s41598-022-10859-9.","journal-title":"Sci Rep"},{"key":"1187_CR17","doi-asserted-by":"publisher","unstructured":"Tamada T, et al.\u00a0Comparison of biparametric and multiparametric MRI for clinically significant prostate cancer detection with PI-RADS version 2.1. J Magn Reson Imaging. 2021;53(1):283\u2013291.\u00a0https:\/\/doi.org\/10.1002\/jmri.27283.","DOI":"10.1002\/jmri.27283"},{"issue":"5","key":"1187_CR18","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s00261-019-01934-3","volume":"44","author":"M Gatti","year":"2019","unstructured":"Gatti M, et al. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdom Radiol (NY). 2019;44(5):1883\u201393. https:\/\/doi.org\/10.1007\/s00261-019-01934-3.","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"1187_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00261-016-0871-z","volume":"42","author":"E Hassanzadeh","year":"2017","unstructured":"Hassanzadeh E, et al. Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review. Abdom Radiol (NY). 2017;42(1):278\u201389. https:\/\/doi.org\/10.1007\/s00261-016-0871-z.","journal-title":"Abdom Radiol (NY)"},{"issue":"9","key":"1187_CR20","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1007\/s00261-021-03035-6","volume":"46","author":"J Abreu-Gomez","year":"2021","unstructured":"Abreu-Gomez J, et al. Pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI in PI-RADS category 3 peripheral zone lesions: preliminary study evaluating DCE-MRI as an imaging biomarker for detection of clinically significant prostate cancers. Abdom Radiol (NY). 2021;46(9):4370\u201380. https:\/\/doi.org\/10.1007\/s00261-021-03035-6.","journal-title":"Abdom Radiol (NY)"},{"key":"1187_CR21","doi-asserted-by":"publisher","unstructured":"Rico L, et al.\u00a0PI-RADS 3 lesions: does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer? Urol Oncol. 2021;(7):431 e9\u2013431 e13. https:\/\/doi.org\/10.1016\/j.urolonc.2020.11.010.","DOI":"10.1016\/j.urolonc.2020.11.010"},{"issue":"3","key":"1187_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1148\/radiol.2016152542","volume":"280","author":"AB Rosenkrantz","year":"2016","unstructured":"Rosenkrantz AB, et al. Interobserver reproducibility of the PI-RADS version 2 lexicon: a multicenter study of six experienced prostate radiologists. Radiology. 2016;280(3):793\u2013804. https:\/\/doi.org\/10.1148\/radiol.2016152542.","journal-title":"Radiology"},{"key":"1187_CR23","doi-asserted-by":"publisher","unstructured":"Natale C, et al.\u00a0Considering predictive factors in the diagnosis of clinically significant prostate cancer in patients with PI-RADS 3 lesions. Life (Basel). 2021;11(12).\u00a0https:\/\/doi.org\/10.3390\/life11121432.","DOI":"10.3390\/life11121432"},{"issue":"5","key":"1187_CR24","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00345-020-03352-3","volume":"39","author":"M Kim","year":"2021","unstructured":"Kim M, et al. Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion? World J Urol. 2021;39(5):1463\u201371. https:\/\/doi.org\/10.1007\/s00345-020-03352-3.","journal-title":"World J Urol"},{"issue":"3","key":"1187_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","volume":"6","author":"M Maggi","year":"2020","unstructured":"Maggi M, et al. Prostate Imaging Reporting and Data System 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. 2020;6(3):463\u201378. https:\/\/doi.org\/10.1016\/j.euf.2019.06.014.","journal-title":"Eur Urol Focus"},{"key":"1187_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34355","author":"AM Fang","year":"2022","unstructured":"Fang AM, et al. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions. Cancer. 2022. https:\/\/doi.org\/10.1002\/cncr.34355.","journal-title":"Cancer"},{"key":"1187_CR27","doi-asserted-by":"publisher","unstructured":"Osses DF, et al.\u00a0Equivocal PI-RADS three lesions on prostate magnetic resonance imaging: risk stratification strategies to avoid MRI-targeted biopsies. J Pers Med. 2020;10(4).\u00a0https:\/\/doi.org\/10.3390\/jpm10040270.","DOI":"10.3390\/jpm10040270"},{"issue":"1","key":"1187_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1148\/radiol.212692","volume":"306","author":"AA Tavakoli","year":"2023","unstructured":"Tavakoli AA, et al. Contribution of dynamic contrast-enhanced and diffusion MRI to PI-RADS for detecting clinically significant prostate cancer. Radiology. 2023;306(1):186\u201399. https:\/\/doi.org\/10.1148\/radiol.212692.","journal-title":"Radiology"},{"issue":"6","key":"1187_CR29","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.2214\/ajr.17.18008","volume":"209","author":"ER Felker","year":"2017","unstructured":"Felker ER, et al. Risk stratification among men with Prostate Imaging Reporting and Data System version 2 category 3 transition zone lesions: is biopsy always necessary? AJR Am J Roentgenol. 2017;209(6):1272\u20137. https:\/\/doi.org\/10.2214\/ajr.17.18008.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"1187_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1148\/radiol.2019181749","volume":"291","author":"EW Johnston","year":"2019","unstructured":"Johnston EW, et al. VERDICT MRI for prostate cancer: intracellular volume fraction versus apparent diffusion coefficient. Radiology. 2019;291(2):391\u20137. https:\/\/doi.org\/10.1148\/radiol.2019181749.","journal-title":"Radiology"},{"issue":"8","key":"1187_CR31","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00345-018-2565-3","volume":"37","author":"TJ Kim","year":"2019","unstructured":"Kim TJ, et al. Outcomes of magnetic resonance imaging fusion-targeted biopsy of prostate imaging reporting and data system 3 lesions. World J Urol. 2019;37(8):1581\u20136. https:\/\/doi.org\/10.1007\/s00345-018-2565-3.","journal-title":"World J Urol"},{"key":"1187_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ejrad.2017.08.017","volume":"95","author":"NL Hansen","year":"2017","unstructured":"Hansen NL, et al. Sub-differentiating equivocal PI-RADS-3 lesions in multiparametric magnetic resonance imaging of the prostate to improve cancer detection. Eur J Radiol. 2017;95:307\u201313. https:\/\/doi.org\/10.1016\/j.ejrad.2017.08.017.","journal-title":"Eur J Radiol"},{"issue":"12","key":"1187_CR33","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s11255-022-03351-w","volume":"54","author":"AS Knight","year":"2022","unstructured":"Knight AS, Sharma P, de Riese WTW. MRI determined prostate volume and the incidence of prostate cancer on MRI-fusion biopsy: a systemic review of reported data for the last 20 years. Int Urol Nephrol. 2022;54(12):3047\u201354. https:\/\/doi.org\/10.1007\/s11255-022-03351-w.","journal-title":"Int Urol Nephrol"},{"key":"1187_CR34","doi-asserted-by":"publisher","unstructured":"Al Hussein Al Awamlh B, et al.\u00a0Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions. Urol Oncol. 2020;38(7):637.e9\u2013637 e15.\u00a0https:\/\/doi.org\/10.1016\/j.urolonc.2020.03.019.","DOI":"10.1016\/j.urolonc.2020.03.019"},{"issue":"2","key":"1187_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2214\/ajr.17.18516","volume":"210","author":"AD Sheridan","year":"2018","unstructured":"Sheridan AD, et al. Risk of clinically significant prostate cancer associated with Prostate Imaging Reporting and Data System category 3 (equivocal) lesions identified on multiparametric prostate MRI. AJR Am J Roentgenol. 2018;210(2):347\u201357. https:\/\/doi.org\/10.2214\/ajr.17.18516.","journal-title":"AJR Am J Roentgenol"},{"key":"1187_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.urology.2021.11.033","volume":"164","author":"JJ Tosoian","year":"2022","unstructured":"Tosoian JJ, et al. Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need. Urology. 2022;164:184\u201390. https:\/\/doi.org\/10.1016\/j.urology.2021.11.033.","journal-title":"Urology"},{"key":"1187_CR37","doi-asserted-by":"publisher","unstructured":"Cao Y, et al.\u00a0The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer. Oncotarget. 2017;8(27):44040\u201344049.\u00a0https:\/\/doi.org\/10.18632\/oncotarget.17182.","DOI":"10.18632\/oncotarget.17182"},{"issue":"1","key":"1187_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/bco2.8","volume":"1","author":"H Klocker","year":"2020","unstructured":"Klocker H, et al. Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer. BJUI Compass. 2020;1(1):15\u201320. https:\/\/doi.org\/10.1002\/bco2.8.","journal-title":"BJUI Compass"},{"key":"1187_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.euros.2021.12.009","volume":"37","author":"J Morote","year":"2022","unstructured":"Morote J, et al. Improving the early detection of clinically significant prostate cancer in men in the challenging Prostate Imaging-Reporting and Data System 3 category. Eur Urol Open Sci. 2022;37:38\u201344. https:\/\/doi.org\/10.1016\/j.euros.2021.12.009.","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"1187_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.remn.2017.07.004","volume":"37","author":"JR Garc\u00eda Garz\u00f3n","year":"2018","unstructured":"Garc\u00eda Garz\u00f3n JR, et al. (68)Ga-PSMA PET\/CT in prostate cancer. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018;37(2):130\u20138. https:\/\/doi.org\/10.1016\/j.remn.2017.07.004.","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"issue":"5","key":"1187_CR41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/pros.24475","volume":"83","author":"J Yang","year":"2023","unstructured":"Yang J, et al. The use of (68) Ga-PSMA PET\/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk. Prostate. 2023;83(5):430\u20139. https:\/\/doi.org\/10.1002\/pros.24475.","journal-title":"Prostate"},{"issue":"5","key":"1187_CR42","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/jmri.27692","volume":"54","author":"SJ Hectors","year":"2021","unstructured":"Hectors SJ, et al. Magnetic resonance imaging radiomics-based machine learning prediction of clinically significant prostate cancer in equivocal PI-RADS 3 lesions. J Magn Reson Imaging. 2021;54(5):1466\u201373. https:\/\/doi.org\/10.1002\/jmri.27692.","journal-title":"J Magn Reson Imaging"},{"issue":"11","key":"1187_CR43","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.1007\/s00330-020-06958-8","volume":"30","author":"Y Kan","year":"2020","unstructured":"Kan Y, et al. Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation. Eur Radiol. 2020;30(11):6274\u201384. https:\/\/doi.org\/10.1007\/s00330-020-06958-8.","journal-title":"Eur Radiol"},{"issue":"12","key":"1187_CR44","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1007\/s00261-020-02678-1","volume":"45","author":"Y Hou","year":"2020","unstructured":"Hou Y, et al. A radiomics machine learning-based redefining score robustly identifies clinically significant prostate cancer in equivocal PI-RADS score 3 lesions. Abdom Radiol (NY). 2020;45(12):4223\u201334. https:\/\/doi.org\/10.1007\/s00261-020-02678-1.","journal-title":"Abdom Radiol (NY)"},{"key":"1187_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.825429","volume":"11","author":"T Li","year":"2021","unstructured":"Li T, et al. Development and validation of a radiomics nomogram for predicting clinically significant prostate cancer in PI-RADS 3 lesions. Front Oncol. 2021;11: 825429. https:\/\/doi.org\/10.3389\/fonc.2021.825429.","journal-title":"Front Oncol"},{"key":"1187_CR46","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Jin P, et al. Utility of clinical-radiomic model to identify clinically significant prostate cancer in biparametric MRI PI-RADS V2.1 category 3 lesions. Front Oncol. 2022;12:840786. https:\/\/doi.org\/10.3389\/fonc.2022.840786. The study found that the clinical-radiomic model could effectively identify csPCa among biparametric PI-RADS 3 lesions and thus could help avoid unnecessary biopsy and improve the life quality of patients. This study is one of the representatives of the radiomics research on PI-RADS 3 lesions.","DOI":"10.3389\/fonc.2022.840786"},{"issue":"7","key":"1187_CR47","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/diagnostics12071565","volume":"12","author":"M Gravina","year":"2022","unstructured":"Gravina M, et al. Machine learning and clinical-radiological characteristics for the classification of prostate cancer in PI-RADS 3 lesions. Diagnostics (Basel). 2022;12(7):1565. https:\/\/doi.org\/10.3390\/diagnostics12071565.","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"1187_CR48","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41591-021-01506-3","volume":"27","author":"I Dayan","year":"2021","unstructured":"Dayan I, et al. Federated learning for predicting clinical outcomes in patients with COVID-19. Nat Med. 2021;27(10):1735\u201343. https:\/\/doi.org\/10.1038\/s41591-021-01506-3.","journal-title":"Nat Med"},{"issue":"7553","key":"1187_CR49","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature14539","volume":"521","author":"Y LeCun","year":"2015","unstructured":"LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436\u201344. https:\/\/doi.org\/10.1038\/nature14539.","journal-title":"Nature"},{"issue":"1","key":"1187_CR50","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41598-022-07217-0","volume":"12","author":"N Singhal","year":"2022","unstructured":"Singhal N, et al. A deep learning system for prostate cancer diagnosis and grading in whole slide images of core needle biopsies. Sci Rep. 2022;12(1):3383. https:\/\/doi.org\/10.1038\/s41598-022-07217-0.","journal-title":"Sci Rep"},{"key":"1187_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42256-020-0200-7\u25cf\u25cf","volume":"2","author":"Y Tolkach","year":"2020","unstructured":"\u2022\u2022\u00a0Tolkach Y, et al. High-accuracy prostate cancer pathology using deep learning. Nat Mach Intell. 2020;2:1\u20138.\u00a0https:\/\/doi.org\/10.1038\/s42256-020-0200-7.\u00a0The study found that the overall accuracy of our model for tumor detection in two validation cohorts is comparable to that of pathologists and reaches 97.3% in a native version and more than 98% using the suggested DL-based augmentation strategies. This study inspired the use of deep learning models to predict the nature of PI-RADS 3 lesions.","journal-title":"Nature Machine Intelligence"},{"issue":"4","key":"1187_CR52","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41416-020-01122-x","volume":"124","author":"A Echle","year":"2021","unstructured":"Echle A, et al. Deep learning in cancer pathology: a new generation of clinical biomarkers. Br J Cancer. 2021;124(4):686\u201396. https:\/\/doi.org\/10.1038\/s41416-020-01122-x.","journal-title":"Br J Cancer"},{"issue":"10","key":"1187_CR53","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00345-019-03000-5","volume":"38","author":"R Suarez-Ibarrola","year":"2020","unstructured":"Suarez-Ibarrola R, et al. Current and future applications of machine and deep learning in urology: a review of the literature on urolithiasis, renal cell carcinoma, and bladder and prostate cancer. World J Urol. 2020;38(10):2329\u201347. https:\/\/doi.org\/10.1007\/s00345-019-03000-5.","journal-title":"World J Urol"},{"issue":"1131","key":"1187_CR54","doi-asserted-by":"publisher","first-page":"20210563","DOI":"10.1259\/bjr.20210563","volume":"95","author":"B Turkbey","year":"2022","unstructured":"Turkbey B, Haider MA. Deep learning-based artificial intelligence applications in prostate MRI: brief summary. Br J Radiol. 2022;95(1131):20210563. https:\/\/doi.org\/10.1259\/bjr.20210563.","journal-title":"Br J Radiol"},{"issue":"3","key":"1187_CR55","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1148\/radiol.2019192012","volume":"293","author":"AR Padhani","year":"2019","unstructured":"Padhani AR, Turkbey B. Detecting prostate cancer with deep learning for MRI: a small step forward. Radiology. 2019;293(3):618\u20139. https:\/\/doi.org\/10.1148\/radiol.2019192012.","journal-title":"Radiology"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-023-01187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-023-01187-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-023-01187-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T04:47:16Z","timestamp":1703306836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-023-01187-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1187"],"URL":"https:\/\/doi.org\/10.1007\/s11934-023-01187-0","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"21 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors were performed in accordance with all applicable ethical standards including the Helsinki Declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}